الفهرس | Only 14 pages are availabe for public view |
Abstract The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, the production and the manufacturing limitations to insure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutnin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused essentially on improving the production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe production, while adjuvants, dose alternate delivery routes and variations, which could target the vaccine immunogenicity improvements. Influenza virus-like particle (VLPs), viral antigens lack nucleic acids which are non-infectious, limit the risk of recombination with wild-type strains. This study focused on producing an Egyptian Avian influenza VLP isolate (A/Turkey/Egypt/7/2007 (H5N1)) generated by using baculovirus expression system into SF9 cells, where the HA & M1 genes were sub-cloned into TA cloning vector; farther cloned into pAcAB4 Baculovirus Transfer Vector. The generated influenza VLPs were observed photographed by transmitted electron microscope (TEM) and detected by measuring HA activity (22 HAU/25μl), hemadsorbtion activit, SDS-PAGE, and Western blot. This study discuss the preliminary creation of identified Egyptian isolate influenza VLPs vaccine in Baculovirus expression& insect cell system which could be in large scale is more rapid and easy than other production technologies. It is essential that further immune response studies on the Egyptian isolate generated Influenza VLPs to be carried out. |